NCT02873325

Registry on Salvage Antiviral Treatment for Patients Experiencing ADV and / or CMV Reactivation Post Allogeneic HSCT

European Patient Registry on Salvage Antiviral Treatment for Patients Experiencing Adenovirus and / or Cytomegalovirus Reactivation Post Allogeneic Hematopoietic Stem Cell Transplantation

• Status: Terminated
• Phase: —
• Study type: Observational
• Enrollment: 1 (actual)
• Sponsor: Cell Medica Ltd · Industry
• Sex: All
• Age: —
• Healthy volunteers: Not accepted

Summary

DESIGN: Disease registry - non-interventional. INDICATION: Patients failing first or subsequent line treatment for adenovirus and / or cytomegalovirus reactivation post allogeneic hematopoietic stem cell transplantation.

Detailed description

In this disease registry, data on approximately 120 allo HSCT patients who have received salvage treatment (second or later line) with any antiviral therapy for ADV and / or CMV post allogeneic HSCT will be documented; of these 120, at least 40 patients will have been treated with Cell Medica's immune reconstitution ACT as salvage therapy. The patients will be consented prospectively or retrospectively for collection of data. Data will be collected at baseline, 6 months and 1 year after commencement of salvage treatment. Retrospective data collection (for patients who underwent HSCT in 2010 or later) is permitted.

Conditions

• Infectious Complications Following HSCT

Interventions

Type	Name	Description
OTHER	antiviral therapies for CMV and/or ADV	salvage antiviral treatments for ADV and/or CMV

Timeline

• Start date: 2016-05-11
• Primary completion: 2017-02-23
• Completion: 2017-02-23
• First posted: 2016-08-19
• Last updated: 2018-02-01

Locations

2 sites across 1 country: United Kingdom